
SITC's Cancer Immunotherapy Guidelines program is a collection of clinical practice guidelines (CPGs) developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure recommendations are unbiased, transparent, and balanced.
This guidelines addresses some of the most commonly reported toxicities during treatment with FDA-approved CAR T cell therapies as well as other emerging IEC therapies, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and persistent cytopenias and resultant infections, among other key considerations for oncologists treating their patients with these agents.
A companion guideline on the management of immune checkpoint inhibitor-related adverse events published on June 25, 2021 in the Journal for ImmunoTherapy of Cancer (JITC).